HTA ID Drug Brand Indication Assessment status Date
22062 Macimorelin acetate Ghryvelin® For the diagnosis of growth hormone deficiency (GHD) in adults. Rapid Review Complete 20th October 2023
- Macitentan Opsumit® Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III. Rapid Review Complete 31st January 2014
- Magnesium Aspartate Dihydrate Magnaspartate® For the treatment and prevention of magnesium deficiency as diagnosed by a doctor. Magnaspartate is indicated in adults, children and adolescents aged from 2 years.   Rapid Review Complete 14th May 2019
- Mannitol Dry Powder Bronchitol® Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF) Assessment Process Complete 29th April 2019
22069 Maribavir Livtencity® For the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant or solid organ transplant. Rapid Review Complete 14th March 2024
23028 Mavacamten Camzyos® Mavacamten (Camzyos®) is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II–III), obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. Full HTA submission received from Applicant 20th December 2023
- Melatonin Circadin® Prolonged release melatonin (Circadin®) for the short-term treatment of primary insomnia. Full HTA Assessment 21st October 2008
22048 Melatonin Slenyto® For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient. Rapid Review Complete 9th August 2022
23067 Melphalan flufenamide Pepaxti® Melphalan flufenamide (Pepaxti®) is indicated in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least three years from transplantation. Rapid Review Complete 15th December 2023
- Mepolizumab Nucala® Is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients. Assessment Process Complete 1st March 2017
- Mepolizumab Nucala® Mepolizumab 100mg solution in pre-filled pen and mepolizumab 100mg solution in pre-filled syringe are indicated for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and over. Rapid Review Complete 5th November 2019
20007 Meropenem/vaborbactam Vaborem® Is indicated for the treatment of the above infections in adults. Rapid Review Complete 2nd April 2020
- Methoxyflurane Penthrox® For the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses. Rapid Review Complete 18th December 2015
19049 Methyl aminolevulinate Metvix® For the treatment of: thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp, when other therapies are considered less appropriate; superficial and/or nodular basal cell carcinoma unsuitable for other available therapies; and squamous cell carcinoma in situ (Bowen´s disease) when surgical excision is considered less appropriate. Rapid Review Complete 18th December 2019
- Midostaurin Rydapt® Is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive. Assessment Process Complete 5th December 2019
- Midostaurin Rydapt® Midostaurin is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). Suspended 16th October 2018
- Mifamurtide Mepact® For the treatment of osteosarcoma. Rapid Review Complete 13th July 2010
- Migalastat Galafold® For the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. Assessment Process Complete 1st June 2017
- Mirabegron Betmiga® Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Rapid Review Complete 12th March 2013
23040 Mirikizumab Omvoh® Mirikizumab (Omvoh®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. Rapid Review Complete 24th August 2023
20061 Mogamulizumab Poteligeo® For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. NCPE Assessment Process Complete 6th July 2023
21060 Molnupiravir Lagevrio® For the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. Rapid Review Complete 24th December 2021
24002 Momelotinib Omjjara® Momelotinib (Omjjara®) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. Rapid Review Complete 22nd February 2024
21051 Mometasone furoate plus olopatadine Ryaltris® Is indicated for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older. Rapid Review Complete 22nd December 2021
23023 Mosunetuzumab Lunsumio® Mosunetuzumab (Lunsumio®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. Full HTA submission received from Applicant 22nd February 2024